Heart Failure Clinical Trials

The heart failure clinical trials team is interested in seeing how exciting new heart failure drugs and devices can help to improve the outcomes and quality of life for those living with the heart failure disease. 

Feel free to call or e-mail the Knight Cardiovascular Institute research team at 503-418-1964 or by emailing heartresearch@ohsu.edu. You will then be forwarded to the appropriate research team member who will be able to see if you qualify for any of the clinical trials being offered at OHSU. 

You can also find all the of heart failure clinical trials, that are currently enrolling patients, below. 

aCRT-ELSYNC

Adaptive CRT Effect on Electrical Dyssynchrony

Primary investigator:

Larisa Tereshchenko, M.D., P.h.D.

Sub investigators:

Protocol number:

IRB00011299

Study purpose:

The purpose of this study is to better understand how adaptive cardiac resynchronization therapy (aCRT) might benefit patients. aCRT works by sometimes giving stimulation to only the left side of the heart, rather than to both sides, depending on how it senses the heart is functioning. CRT without the adaptive algorithm works by giving stimulation to both sides of the heart. aCRT has already been approved by the FDA and is being used in patients now, but it is not clear which patients it should be used in compared to normal CRT. This study will include patients who are already scheduled to get a CRT device. The investigators will then randomize patients to the aCRT study arm or to the CRT study arm. After 6 months, the investigators will assess the electrical activity of the patients' hearts. After this time, the patient and their doctors will be able to decide if they would like to change the type CRT they have been designated.

Contact:

Nichole Rogovoy (Study Coordinator)
503-418-1964
heartresearch@ohsu.edu 

ALt FLOW

Early Feasibility Study of the Edwards Transcatheter Atrial Shunt System

Adaptive CRT Effect on Electrical Dyssynchrony

Primary investigator:

Firas Zahr, M.D.

Sub investigators:

Protocol number:

IRB00018639

Study purpose:

The purpose of the study is to learn about the safety, functionality, and effectiveness of the Edwards Transcatheter Atrial Shunt System in patients with symptomatic left heart failure. 

Contact:

Sarah Fishbein (Study Coordinator)
503-418-1964
heartresearch@ohsu.edu 

BeAT-HF

Barostim Neo® - BarofleActivation Therapy for Heart Failure

Primary investigator:

Albert Camacho, M.D.

Protocol number:

IRB00015725

Study purpose:

The purpose of this study is to learn if the study device is safe and works in improving heart failure symptoms as well as the quality of life for those living with heart failure. The study device is meant to stimulate an artery in the neck that will send signals to the brain telling blood vessels to relax, the heart to slow down and stop sending stress hormones, and the kidneys to reduce the amount of fluid in the body.

Contact:

John Halvorson (Study Coordinator)
503-418-1964
heartresearch@ohsu.edu 

CAPACITY-HF

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Safety and Efficacy of Different Doses of IW-1973 over 12 Weeks in Patients with Heart Failure with Preserved Ejection Fraction (CAPACITY HFpEF)

Primary investigator:

Albert Camacho, M.D.

Sub investigators:

Protocol number:

IRB00017719

Study purpose:

The purpose of this study is to learn more about a study drug called IW1973-204 and how it can help to improve exercise capacity in those with heart failure with preserved ejection fraction. 

Contact:

John Halvorson (Study Coordinator)
503-418-1964
heartresearch@ohsu.edu 

COAPT-CAS

Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional MR (COAPT) Continuing Access Study

Primary investigator:

Sub investigators:

Protocol number:

IRB00017739

Study purpose:

The purpose of this study is to learn about treatments for patients with mitral valve regurgitation and heart failure with the use of the MitraClip device. This study is designed to learn more about the safety and effectiveness of the MitraClip device. Only patients with Medicare as their primary insurer are being enrolled for this study at this time. 

Contact:

Sarah Fishbein (Study Coordinator)
503-418-1964
heartresearch@ohsu.edu 

HCM Pilot Study

Hypertrophic Cardiomyopathy Pilot Study

Primary investigator:

Larisa Tereshchenko, M.D., Ph.D.

Sub investigators:

Protocol number:

IRB00015049

Study purpose:

This study evaluates mechanisms of arrythmogenicity in hypertrophic cardiomyopathy, in comparison to patients with well-understood arrhythmogenic substrate (ischemic cardiomyopathy), as well as to individuals free from arrhythmogenic substrate.

Contact:

Nichole Rogovoy (Study Coordinator)
503-418-1964
heartresearch@ohsu.edu 

LIFE STUDY

Entresto™(LCZ696) in Advance Heart Failure

Primary investigator:

Albert Camacho, M.D.

Protocol number:

IRB00016277

Study purpose:

The purpose of this study is to test whether the study drug (Entresto®) improves heart failure symptoms and outcomes in persons with advanced heart failure in comparison to treatment with valsartan alone over 24 weeks. 

Contact:

John Halvorson (Study Coordinator)
503-418-1964
heartresearch@ohsu.edu 

MOMENTUM 3

Multi-Center Study oMaglev Technology in Patients Undergoing MCS Therapy in HeartMate 3

Primary investigator:

Frederick Tibayan, M.D.

Protocol number:

IRB00016427

Study purpose:

The purpose of this study is to evaluate the effect of the investigational drug, mavacamten, compared to a placebo (an inactive drug) in patients with non-obstructive HCM. This is being done to confirm that mavacamten is safe, and can be tolerated and to study whether it helps to improve symptoms or ability to exercise.

Contact:

John Halvorson (Study Coordinator)
503-418-1964
heartresearch@ohsu.edu 

MYK-491-003 HF-SAD

Randomized, Double-blind, Crossover, Placebo-controlled, Adaptive Design Study of Safety, Tolerability, Preliminary Pharmacokinetics, and Pharmacodynamics of Single Ascending Oral Doses of MYK-491 in Patients with Stable Heart Failure.

Primary investigator:

Albert Camacho, M.D.

Sub investigators:

Protocol number:

IRB00017910

Study purpose:

The purpose of this study is to learn more about a study drug called MYK-491. This will be an inpatient study to determine if the study drug will help the heart pump more efficiently with each beat, if the study drug is safe in those with heart failure, what the side effects of the drug is, and how much of the drug is in the blood.

Contact:

John Halvorson (Study Coordinator)
503-418-1964
heartresearch@ohsu.edu 

TAVR UNLOAD

Transcatheter Aortic Valve Replacement to Unload the LEft Ventricle in Patients with Advanced Heart Failure: A Randomized Trial (TAVR UNLOAD)

Primary investigator:

Sub investigators:

Protocol number:

IRB00015224

Study purpose:

The purpose of this study is to learn more about treatment for patients with heart failure and moderate aortic valve stenosis with the use of the TAVR System. This study is designed to compare the safety and effectiveness of the TAVR system versus the current standard of care for heart failure patients.

Contact:

Sarah Fishbein (Study Coordinator)
503-418-1964
heartresearch@ohsu.edu